NY Times
JANUARY 22, 2021
After the surprise discovery of an extra dose in every vial, Pfizer executives successfully lobbied the F.D.A. to change the vaccine’s formal authorization language. The company charges by the dose.
pharmaphorum
JANUARY 29, 2021
Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. ‘Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literall
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JANUARY 25, 2021
The 2021 International Clinical Researcher of the Year competition will continue the successes of last year and be conducted virtually.
Outsourcing Pharma
JANUARY 25, 2021
Two leaders from the clinical technology solutions company discuss how digital tools like eCOAs have been invaluable in facing pandemic-related challenges.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Marketing Network
JANUARY 27, 2021
2020 was a year defined by unexpected challenges – and related opportunity – for pharmaceutical marketers. Some Key Discussion Topics Include: What have we learned about how to create connection within this new paradigm? Which recent innovations are poised to become the best practices that will create measurable impact in 2021? Tune in to listen to the Pharma Marketing Network and leading experts from GSK, Otsuka & Bayer as we navigate these trends and discuss what you need to know to
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for ENVARSUS+XR Envarsus Xr is a drug marketed by Veloxis Pharms Inc and is included in one NDA. There are seventeen patents protecting this drug. Drug…. The post New patent for Veloxis Pharms drug ENVARSUS XR appeared first on DrugPatentWatch - Make Better Decisions.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 7, 2021
The European Union has approved the coronavirus vaccine from Moderna, leaving the UK trailing because of changes to post-Brexit drug approval rules. With the UK reeling from one of the worst outbreaks of the disease, it’s a worrying situation for one of the countries worst hit by the pandemic that is relying on vaccines to bring the virus under control.
Pharma Times
JANUARY 28, 2021
Study suggests that palbociclib could be used to treat around a fifth of people with TNBC
Pharma Mirror
JANUARY 10, 2021
By Boris Goldstein, Co-Founder & Executive Chairman at Brain Scientific COVID-19 is known for its impacts on a patient’s respiratory system, but it has also been found to affect individuals in unique ways and with varying severity levels depending on their age, risk factors, and comorbidities. Several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients.
Pharma Marketing Network
JANUARY 6, 2021
Throughout the year 2020, pharma marketers were forced to explore new strategies in order to keep up with the many evolving trends. Pharma marketers have quickly learned how to adapt to these trends and are prepared to take on new opportunities in 2021. Five trends that will shape the pharma marketing industry in 2021 include media and tech, location independence, relationships despite digital congestion, questioning systems and doubt in institutions, and feelings around trust and wellness.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
JANUARY 18, 2021
A representative from the global CRO outlines how forces like COVID-19, decentralized studies, globalization and others are driving change in the industry.
NY Times
JANUARY 12, 2021
In their first abortion case since Justice Amy Coney Barrett joined the court, the justices reinstated a requirement that women seeking medication abortions pick up a pill in person.
pharmaphorum
JANUARY 22, 2021
Gilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in the UK and South Africa. According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works.
Pharma Times
JANUARY 4, 2021
KRAS mutations are found in several hard-to-treat cancers
Drug Patent Watch
JANUARY 15, 2021
Annual Drug Patent Expirations for SYMDEKO+%28COPACKAGED%29 Symdeko (copackaged) is a drug marketed by Vertex Pharms Inc and is included in one NDA. There are twenty patents protecting this drug. This…. The post New patent for Vertex Pharms drug SYMDEKO (COPACKAGED) appeared first on DrugPatentWatch - Make Better Decisions.
Pharma Marketing Network
JANUARY 25, 2021
Pharma-Marketing is owned and operated by eHealthcare Solutions. The post PMN WEBINAR: Video, Voice, and Virtual: Applying New Digital Technology to Enhance Customer Experience appeared first on Pharma Marketing Network.
Outsourcing Pharma
JANUARY 18, 2021
A leader from Oracle Health Sciences examines the dynamic, challenging year and highlights creativity and ingenuity displayed by research professionals.
NY Times
JANUARY 11, 2021
Participants with the disease still declined, but much more slowly than those receiving a placebo, investigators say.
pharmaphorum
JANUARY 26, 2021
From telehealth to digital trials, customer engagement to healthcare data, Healthware Group outlines the key trends that are expected to shake up digital health this year. Well, it goes without saying, COVID-19 has resulted in a rapid adoption of digital technologies across all industries, most notably in healthcare. There are several important aspects to these shifts for pharma, biotech and medical device companies, so what can we expect to see over the next 12 months and beyond?
Pharma Times
JANUARY 11, 2021
Partnership will aim to research and implement quantum computing in pharma R&D
Eye on FDA
JANUARY 6, 2021
Each year in January, it is relevant to look back on the activities of FDA during the course of the previous year and look at how it was the same or different from prior years, and to look at trends in new direction. This past year, needless to say was a doozy on all fronts. Let’s begin by looking at approvals. One might have surmised that the advent of the COVID-era might have thrown off new approvals and that NMEs approved would go diminish.
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for GOPRELTO Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. There are six patents protecting this drug. Drug patent litigation…. The post New patent for Genus Lifesciences drug GOPRELTO appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JANUARY 26, 2021
While the change signifies the life-sciences solutions firmâs commitment to help customers and patients, day-to-day functions will remain much the same.
NY Times
JANUARY 31, 2021
Rich countries are cornering the market on coronavirus vaccines, leaving poorer regions as potential breeding grounds for variants, like one found in South Africa, that could make vaccines less effective.
pharmaphorum
JANUARY 18, 2021
Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. According to state epidemiologist Dr Erica Pan, there were a higher-than-expected number of suspected allergic reactions at a community clinic being used to administer the shot, with some people needing medical attention in a 24-hour period.
Pharma Times
JANUARY 18, 2021
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Eye on FDA
JANUARY 11, 2021
Well. They said a lot. A lot more than ever, as one might expect. This past year, FDA issued a whopping 420 press releases, more so by far than any year previously. COVID certainly made a big impact – a whopping 65 percent of FDA press releases had to do with the subject of the pandemic. In late March FDA began issuing Coronavirus Updates labeled as a “Daily Roundup” except they weren’t actually always a daily release – some days got skipped.
Drug Patent Watch
JANUARY 7, 2021
Annual Drug Patent Expirations for GOPRELTO Goprelto is a drug marketed by Genus Lifesciences and is included in one NDA. There are six patents protecting this drug. Drug patent litigation…. The post New patent for Genus Lifesciences drug GOPRELTO appeared first on DrugPatentWatch - Make Better Decisions.
Outsourcing Pharma
JANUARY 26, 2021
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
NY Times
JANUARY 29, 2021
Infectious disease doctors say getting a shot of the J&J vaccine, which has a lower efficacy against the virus than other vaccines, would still be well worthwhile.
pharmaphorum
JANUARY 29, 2021
JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. Now, a study designed to prove its safety has achieved the opposite. The post-marketing safety study showed that Xeljanz (tofacitinib) – used to treat rheumatoid arthritis (RA) – was associated with a higher rate of heart attacks and cancer than a TNF inhibitor in patients aged over 50 with underlying cardiovascular risk factors.
Pharma Times
JANUARY 26, 2021
Lab tests evaluated vaccine's efficacy against UK and South African variants
pharmaphorum
JANUARY 25, 2021
The clinical research community has been disrupted in a number of ways due to COVID-19 and sparked a spirit of collaboration and innovation. Worldwide Clinical Trial’s Aman Khera gives five predictions of how clinical research could change in 2021. The pandemic has propelled the life science industry toward higher expectations for faster, more responsive and more inclusive drug development.
pharmaphorum
JANUARY 8, 2021
The Pfizer/BioNTech vaccine appears to work against an important mutation in the new coronavirus variants causing havoc in the UK and South Africa, according to research from the drugs giant. Findings of the lab study posted online have not yet been peer reviewed but provide some reassurance for countries like the UK, which are relying on vaccines to bring the pandemic under control.
pharmaphorum
JANUARY 27, 2021
Back in 2017, the UK biotech RedX Pharma had to sell its prized asset after administrators stepped in to stave off a debt crisis, with Loxo Oncology snapping up the BTK inhibitor for $40 million. That drug, now known as LOXO-305 was one of the stars of the American Society of Haematology (ASH) conference in December, finding its way into Eli Lilly’s pipeline after the big pharma’s $8 billion takeover of Loxo.
Expert insights. Personalized for you.
144 
Let's personalize your content